MedTrace Logo

Evaluation of Safety and Efficacy of PDP-716

NCT03450629 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 682

Last updated 2022-02-15

Study results available
· View outcomes & findings →

Summary

The study will be conducted to evaluate the efficacy and safety of topical administration of PDP-716 compared with brimonidine tartrate ophthalmic solution.

Conditions

Interventions

DRUG

Brimonidine Tartrate Ophthalmic Suspension

PDP-716

DRUG

Brimonidine Tartrate Ophthalmic Solution

Three Times Brimonidine Tartrate Ophthalmic Solution

Sponsors & Collaborators

  • Sun Pharma Advanced Research Company Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-13
Primary Completion
2020-12-01
Completion
2020-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03450629 on ClinicalTrials.gov